Departamento académico
(FM) Urología
Articles (11) Publications in which a researcher has participated
2022
-
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E
Bladder Cancer, Vol. 8, Núm. 4, pp. 379-393
-
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high–grade non-muscle-invasive urothelial bladder cancer
Urologic Oncology: Seminars and Original Investigations, Vol. 40, Núm. 11, pp. 491.e11-491.e19
-
Approach to Lower Urinary Tract Reconstruction: A Survey of Adult and Pediatric Urologist Perspectives and Experiences
Frontiers in Urology, Vol. 2
-
Comparison of surgical approaches to radical prostatectomy in our series beyond oncological and functional outcomes
Actas Urologicas Espanolas, Vol. 46, Núm. 5, pp. 275-284
-
Evidence-based Medicine: Perceptions, Attitudes, and Skills Among European Urology Residents
European Urology Open Science, Vol. 45, pp. 44-49
-
Evolution of renal function in patients with cT1 renal tumors after laparoscopic partial and radical nephrectomy. Predictive factors for renal function impairment
Actas Urologicas Espanolas, Vol. 46, Núm. 2, pp. 63-69
-
Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
European Urology Open Science, Vol. 40, pp. 38-45
-
Laparoscopic nephron sparing surgery and radical nephrectomy in cT1 renal tumors. Comparative analysis of complications and survival
Actas Urologicas Espanolas, Vol. 46, Núm. 6, pp. 340-347
-
Metastatic testicular cancer presenting with hematuria and flank pain
Urology Annals, Vol. 14, Núm. 2, pp. 196-198
-
Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: A retrospective cohort from a high-volume center
Urologic Oncology: Seminars and Original Investigations, Vol. 40, Núm. 7, pp. 345.e19-345.e23
-
Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial
World Journal of Urology, Vol. 40, Núm. 4, pp. 999-1004